Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 3/20 | 0.49 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.49 |
| ▸ | MCHR1 | Q99705 | 14/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14685177 | 0.85 | CYP11B1 (0.42) | CYP11B1CYP11B2MCHR1 | |
| SCHEMBL14685287 | 0.81 | MCHR1 (0.43) | MCHR1PDE10AALDH1A1LMNATSHR | |
| SCHEMBL14685307 | 0.79 | PDE10A (0.51) | MCHR1PDE10A | |
| SCHEMBL14685181 | 0.78 | PDE10A (0.36) | CYP11B2MCHR1PDE10AALDH1A1LMNA | |
| SCHEMBL22145958 | 0.76 | CYP11B1 (0.56) | CYP11B1CYP11B2ALDH1A1LMNATSHR | |
| SCHEMBL14685288 | 0.76 | MCHR1 (0.54) | CYP11B1CYP11B2MCHR1 | |
| SCHEMBL14685178 | 0.76 | ALDH1A1 (0.47) | MCHR1PDE10AALDH1A1TSHR | |
| SCHEMBL17237853 | 0.74 | PDE10A (0.52) | CYP11B1CYP11B2PDE10AALDH1A1 | |
| SCHEMBL16160312 | 0.71 | CYP11B1 (0.51) | CYP11B1CYP11B2ALDH1A1 | |
| SCHEMBL14685158 | 0.71 | GAA (0.40) | CYP11B1CYP11B2MCHR1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2740730-B1 | DIBENZOOXEPIN DERIVATIVE | KYOWA HAKKO KIRIN CO LTD (JP) | 2016-11-16 | — | — | EP | disclosed |
| US-8969345-B2 | Dibenzooxepin derivative | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2015-03-03 | — | — | US | disclosed |
| US-8969345-B2 | Dibenzooxepin derivative | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2015-03-03 | — | — | US | disclosed |
| US-20140163008-A1 | DIBENZOOXEPIN DERIVATIVE | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2014-06-12 | — | — | US | disclosed |
| WO-2013018899-A1 | DIBENZOOXEPIN DERIVATIVE | 協和発酵キリン株式会社 (JP) | 2013-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140163008-A1 | DIBENZOOXEPIN DERIVATIVE | PPARA, PPARG, PPARD | CYP11B1 250/4885CYP11B2 175/4885MCHR1 3001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.